Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Am J Trop Med Hyg ; 100(5): 1249-1257, 2019 05.
Article in English | MEDLINE | ID: mdl-30860010

ABSTRACT

In 2016, a chikungunya virus (CHIKV) outbreak was reported in Mandera, Kenya. This was the first major CHIKV outbreak in the country since the global reemergence of this virus in Kenya in 2004. We collected samples and sequenced viral genomes from this outbreak. All Kenyan genomes contained two mutations, E1:K211E and E2:V264A, recently reported to have an association with increased infectivity, dissemination, and transmission in the Aedes aegypti vector. Phylogeographic inference of temporal and spatial virus relationships showed that this variant emerged within the East, Central, and South African lineage between 2005 and 2008, most probably in India. It was also in India where the first large outbreak caused by this virus appeared, in New Delhi, 2010. More importantly, our results also showed that this variant is no longer contained to India. We found it present in several major outbreaks, including the 2016 outbreaks in Pakistan and Kenya, and the 2017 outbreak in Bangladesh. Thus, this variant may have a capability of driving large CHIKV outbreaks in different regions of the world. Our results point to the importance of continued genomic-based surveillance and prompt urgent vector competence studies to assess the level of vector susceptibility and virus transmission, and the impact this might have on this variant's epidemic potential and global spread.


Subject(s)
Aedes/virology , Chikungunya Fever/epidemiology , Chikungunya virus/genetics , Disease Outbreaks , Genetic Fitness , Genetic Variation , Mutation , Animals , Bangladesh/epidemiology , Chikungunya Fever/virology , Genome, Viral , Humans , India/epidemiology , Kenya/epidemiology , Mosquito Vectors/virology , Phylogeny , RNA, Viral/genetics
2.
Virol J ; 15(1): 178, 2018 11 22.
Article in English | MEDLINE | ID: mdl-30466469

ABSTRACT

BACKGROUND: Rift Valley Fever (RVF) is a mosquito-borne viral zoonosis. To detect RVF virus (RVFV) infection, indirect immunoglobulin G (IgG) and immunoglobulin M (IgM) enzyme linked immunosorbent assays (ELISAs) which utilize recombinant RVFV nucleocapsid (RVFV-N) protein as assay antigen, have reportedly been used, however, there is still a need to develop more sensitive and specific methods of detection. METHODS: RVFV-N protein was expressed in Escherichia coli (E. coli) and purified by histidine-tag based affinity chromatography. This recombinant RVFV-N (rRVFV-N) protein was then used as antigen to develop an IgG sandwich ELISA and IgM capture ELISAs for human sera. Ninety six serum samples collected from healthy volunteers during the RVF surveillance programme in Kenya in 2013, and 93 serum samples collected from RVF-suspected patients during the 2006-2007 RVF outbreak in Kenya were used respectively, to evaluate the newly established rRVFV-N protein-based IgG sandwich ELISA and IgM capture ELISA systems in comparison with the inactivated virus-based ELISA systems. RESULTS: rRVFV-N protein-based-IgG sandwich ELISA and IgM capture ELISA for human sera were established. Both the new ELISA systems were in 100% concordance with the inactivated virus-based ELISA systems, with a sensitivity and specificity of 100%. CONCLUSIONS: Recombinant RVFV-N is a safe and affordable antigen for RVF diagnosis. Our rRVFV-N-based ELISA systems are safe and reliable tools for diagnosis of RVFV infection in humans and especially useful in large-scale epidemiological investigation and for application in developing countries.


Subject(s)
Antigens, Viral/immunology , Enzyme-Linked Immunosorbent Assay/methods , Nucleocapsid Proteins/immunology , Rift Valley Fever/diagnosis , Rift Valley fever virus/immunology , Virus Inactivation , Animals , Antibodies, Viral/blood , Antigens, Viral/isolation & purification , Escherichia coli/genetics , Healthy Volunteers , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Rabbits , Recombinant Proteins/immunology , Recombinant Proteins/isolation & purification , Rift Valley Fever/immunology , Sensitivity and Specificity , Zoonoses/diagnosis , Zoonoses/immunology , Zoonoses/virology
3.
PLoS One ; 13(10): e0205058, 2018.
Article in English | MEDLINE | ID: mdl-30308064

ABSTRACT

Chikungunya is a reemerging vector borne pathogen associated with severe morbidity in affected populations. Lamu, along the Kenyan coast was affected by a major chikungunya outbreak in 2004. Twelve years later, we report on entomologic investigations and laboratory confirmed chikungunya cases in northeastern Kenya. Patient blood samples were received at the Kenya Medical Research Institute (KEMRI) viral hemorrhagic fever laboratory and the immunoglobulin M enzyme linked immunosorbent assay (IgM ELISA) was used to test for the presence of IgM antibodies against chikungunya and dengue. Reverse transcription polymerase chain reaction (RT-PCR) utilizing flavivirus, alphavirus and chikungunya specific primers were used to detect acute infections and representative PCR positive samples sequenced to confirm the circulating strain. Immature mosquitoes were collected from water-holding containers indoors and outdoors in the affected areas in northeastern Kenya. A total of 189 human samples were tested; 126 from Kenya and 63 from Somalia. 52.9% (100/189) tested positive for Chikungunya virus (CHIKV) by either IgM ELISA or RT-PCR. Sequence analysis of selected samples revealed that the virus was closely related to that from China (2010). 29% (55/189) of the samples, almost all from northeastern Kenya or with a history of travel to northern Kenya, tested positive for dengue IgM antibodies. Entomologic risk assessment revealed high house, container and Breteau indices of, 14.5, 41.9 and 17.1% respectively. Underground water storage tanks were the most abundant, 30.1%, of which 77.4% were infested with Aedes aegypti mosquitoes. These findings confirm the presence of active chikungunya infections in the northeastern parts of Kenya. The detection of dengue IgM antibodies concurrently with chikungunya virus circulation emphasizes on the need for improved surveillance systems and diagnostic algorithms with the capacity to capture multiple causes of arbovirus infections as these two viruses share common vectors and eco-systems. In addition sustained entomological surveillance and vector control programs targeting most productive containers are needed to monitor changes in vector densities, for early detection of the viruses and initiate vector control efforts to prevent possible outbreaks.


Subject(s)
Chikungunya Fever/blood , Chikungunya Fever/epidemiology , Mosquito Vectors/virology , Antibodies, Viral/blood , Biomarkers/blood , Chikungunya Fever/immunology , Chikungunya virus/genetics , Chikungunya virus/immunology , Dengue/blood , Dengue/epidemiology , Dengue/immunology , Disease Outbreaks , Humans , Immunoglobulin M/blood , Kenya/epidemiology , Phylogeny , Risk Factors
4.
PLoS Negl Trop Dis ; 9(4): e0003733, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25923210

ABSTRACT

Dengue appears to be endemic in Africa with a number of reported outbreaks. In February 2013, several individuals with dengue-like illnesses and negative malaria blood smears were identified in Mombasa, Kenya. Dengue was laboratory confirmed and an investigation was conducted to estimate the magnitude of local transmission including a serologic survey to determine incident dengue virus (DENV) infections. Consenting household members provided serum and were questioned regarding exposures and medical history. RT-PCR was used to identify current DENV infections and IgM anti-DENV ELISA to identify recent infections. Of 1,500 participants from 701 households, 210 (13%) had evidence of current or recent DENV infection. Among those infected, 93 (44%) reported fever in the past month. Most (68, 73%) febrile infected participants were seen by a clinician and all but one of 32 participants who reportedly received a diagnosis were clinically diagnosed as having malaria. Having open windows at night (OR = 2.3; CI: 1.1-4.8), not using daily mosquito repellent (OR = 1.6; CI: 1.0-2.8), and recent travel outside of Kenya (OR = 2.5; CI: 1.1-5.4) were associated with increased risk of DENV infection. This survey provided a robust measure of incident DENV infections in a setting where cases were often unrecognized and misdiagnosed.


Subject(s)
Dengue Virus/genetics , Dengue/epidemiology , Disease Outbreaks/history , Adult , Dengue Virus/immunology , Disease Outbreaks/statistics & numerical data , Enzyme-Linked Immunosorbent Assay , Female , History, 21st Century , Humans , Immunoglobulin M/blood , Kenya/epidemiology , Male , Reverse Transcriptase Polymerase Chain Reaction , Risk Factors , Travel
SELECTION OF CITATIONS
SEARCH DETAIL
...